Drug Search Results
More Filters [+]

Colestilan

Alternative Names: colestilan, mci-196, mci196, mci 196
Latest Update: 2023-06-19
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: Phosphate Binder

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: European Medicines Agency | Germany | Ireland | Italy | Portugal | Sweden | United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: Mitsubishi Tanabe
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Colestilan

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Kidney Failure, Chronic|Hyperphosphatemia|Dyslipidemia|Kidney Diseases

Phase 2: Type 2 Diabetes

Phase 1: Hyperphosphatemia|Kidney Failure, Chronic

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2012-002583-27

P3

Terminated

Hyperphosphatemia|Kidney Diseases

2017-01-11

2012-002581-12

P3

Completed

Hyperphosphatemia|Kidney Diseases

2015-01-26

MCI-196-E14

P3

Terminated

Kidney Failure, Chronic|Hyperphosphatemia

2015-01-01

2012-002582-35

P3

Terminated

Hyperphosphatemia|Kidney Diseases

2014-12-17

Recent News Events